openPR Logo
Press release

Autologous Cell Therapy Market: Unmet Medical Needs and Cost-effectiveness of Autologous Cell Therapy Drives Demand

03-27-2017 03:00 PM CET | Health & Medicine

Press release from: Transparency Market Research

Autologous Cell Therapy Market

Autologous Cell Therapy Market

Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell therapy does not even require immunosuppression. The growing number of cancer patients have triggered a significant demand for autologous cell therapy. According to the research report, the global market projected to reach a valuation of US$23.7 bn by the end of 2024 as compared to US$3.8 bn in 2015. During the forecast period of 2016 and 2024, the global market is estimated to exhibit a CAGR of 21.9%.

Read Full Report: http://www.transparencymarketresearch.com/autologus-cell-therapy-market.html

The global market is expected to grow due to the huge pool of unmet medical needs for cell based therapy, growing government support for cell-based research, and rising number of technological innovations in cell based therapies. Currently, cell therapy is considered a promising technique for several conditions such as neurological, orthopedic, oncology, and a wide range of autoimmune diseases. The ability of stem cells to transform into a cartilage, tendon, bone (osteoblast), and muscle has given this market a fresh lease of life. The biggest advantages of autologous cells is the fact that it is relatively cost-effective, allows quick access to blood as it is derived from the patient, ensures easy method of production, and comes with the lowest threat of disease transfusion. All of these factors have been consistently boosting the demand for autologous cell therapy in recent years.

Geographically, the market has been divided into Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. North America holds a dominant position in the global market and is expected to maintain its stance in the coming years as well. The strengthening health care infrastructure and supportive government policies are expected ensure high adoption of autologous cell therapy in North America in the near future. The analysts estimate that Asia Pacific will also register a robust CAGR in the coming years. The growth of this market in Asia pacific will be driven by the proliferating medical tourism industry, increasing contract research activities, and economic growth of certain developing countries such as India and China.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=715

The end users of autologous cell therapy are hospitals, research centers, and ambulatory centers. Of these, the hospitals dominated the global market in 2015 and are expected to continue its dominance till the end of 2024 as the surgical procedures continue to be on the rise across hospitals. The research report indicates that the ambulatory surgical centers segment will also expand at a significant rate in the coming years as it is known to reduce waiting time period before surgery, growing outpatient surgical procedures, high confidentiality and privacy of the data, and cost-effective procedure.

Some of the leading players operating in the global market are Major players operating in this Market are Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co., Inc.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Autologous Cell Therapy Market: Unmet Medical Needs and Cost-effectiveness of Autologous Cell Therapy Drives Demand here

News-ID: 483353 • Views: 237

More Releases from Transparency Market Research

Venous Diseases Treatment Market to Expand at a CAGR of 6.8% from 2022 - 2031
Venous Diseases Treatment Market: Overview The venous diseases treatment market is estimated to attain a valuation of US$ 11.3 Bn by 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6.8% from 2022 to 2031. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of
Medical Imaging Equipment Services Market Future Scope Analysis Report 2022-2031
Medical Imaging Equipment Services Market: Overview The medical imaging equipment services market is estimated to attain a valuation of US$ 29.2 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6.1% from 2022 to 2031. The key objective of the TMR report is to offer a complete assessment of the global market including
Geriatric Care Services Market Revenue Share Detailed Analysis Report 2021-2028
Geriatric Care Services Market: Overview The geriatric care services market is estimated to attain a valuation of US$ 0.7 Bn by the end of 2028, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 5.3% from 2021 to 2028. The key objective of the TMR report is to offer a complete assessment of the global market including major
Medical Device Technologies Market - Current Trends and Future Opportunities Ana …
Medical Device Technologies Market: Overview The medical device technologies market is estimated to attain a valuation of US$ 662.7 Bn by the end of 2028, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.3% from 2021 to 2028. The key objective of the TMR report is to offer a complete assessment of the global market including major

All 5 Releases


More Releases for Autologous

Autologous Cell Therapy Market: Competitive Dynamics & Global Outlook 2024
LP INFORMATION offers a latest published report on Autologous Cell Therapy Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Autologous Cell Therapy market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
Autologous Cell Therapy Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Autologous Cell Therapy Market Analysis and Forecast 2019-2024 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Autologous Cell Therapy market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in
Autologous Cell Therapy Market Demand by 2025: QY Research
This recently published report examines the global Autologous Cell Therapy market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Autologous Cell Therapy market along with its drivers, restraints, and trends. It also classifies the market into different
Autologous Cell Therapy Market : Trend, Analysis
Global Autologous Cell Therapy Market: Overview Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell
Autologous Cell Therapy Market: High Prevalence of Cancer Triggers Demand for Au …
Global Autologous Cell Therapy Market: Overview Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell
Autologous Matrix-induced Chondrogenesis Market 2024 - Analysis and Trends
The leading players operating in the global autologous matrix-induced chondrogenesis (AMIC) market are working towards strengthening their foothold in emerging economies such as Brazil, India, China, Mexico, and South Africa. The strategy to expand to these countries is expected to benefit the companies as they will be able to employ cheaper skilled labor, thereby bringing down the costs of their products. Furthermore, the burgeoning medical tourism industry in these countries